Rongchang Biotech announced that revenue for the third quarter of 2026 was 910 million yuan, up 46.41% year on year; net profit attributable to shareholders of listed companies was 611 million yuan, net profit after deducting non-recurring profit and loss of 73.6917 million yuan. Revenue for the first three quarters of 2026 was 6.764 billion yuan, up 293.28% year on year; net profit attributable to shareholders of listed companies was 5.273 billion yuan, net profit after deducting non-recurring profit and loss of 4.412 billion yuan.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.